(Washington DC, May 24th 2016): Postherpetic Neuralgia (PHN) is a painful condition that can last for months or years, mostly affecting the elderly. Commonly recommended first-line medications include topical lidocaine, antidepressants, and anticonvulsants, but other CNS depressants, including opioids, are frequently utilized. Researchers included Dr. Fred Peyerl, Dr. Victor Khangulov, and Dr. Jeff Skaar from Boston Strategic Partners, Dr. Jeffrey Gudin (Englewood Hospital and Medical Center) and Dr. Kalpana Patel (SCILEX Pharmaceuticals). The team conducted a retrospective analysis to investigate PHN treatment patterns using Electronic Health Record (EHR) Data.
The presentation will be on display at ISPOR today between 3.45pm to 7.45 pm. The poster author discussion hour is scheduled at 6.45pm to 7.45 pm. Visit the authors at booth 32 to learn more about the association between the prevalence of COPD comorbidities and readmission rates. The research is supported by detailed analyses of EHR database which contains information about 60 million unique patients over a 15 year timeframe. More information on this database can be found here.
Please check out our events section for the full list of presentation titles and timetable.
To schedule a meeting with our team, please email us at info@bostonsp.com. We look forward to discussing ideas and insights on health economics and outcomes research and ways to support your business and clinical needs.
About ISPOR
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) advances the policy, science, and practice of pharmacoeconomics (health economics) and outcomes research (the scientific discipline that evaluates the effect of health care interventions on patient well-being including clinical, economic, and patient-centered outcomes).
(Source: http://www.ispor.org/about-ispor.asp)